Love Your Location

Why one of the world's leading life science companies chose Pearland

The Lonza facility in Lower Kirby. Photo courtesy of Pearland Economic Development Corp.

In 2018, Switzerland-based company Lonza debuted a 300,000-square-foot life science facility in Pearland, the largest dedicated cell and gene therapy manufacturing facility in the world at the time.

What made one of the world's largest companies for contract development and manufacturing choose Lower Kirby for this groundbreaking building?

"The location was ideal for the expansion capability, proximity to the Texas Medical Center, and ease of access from major freeways 288 and Beltway 8," says Frank Bugg, Lonza's site head. "Many Lonza employees also reside in the Pearland area."

The company also sought a location for this "Center of Excellence" that would maintain a presence on the "third coast" of biotech. Lonza currently employs more than 500 at its Pearland facility.

Additional factors that made Pearland's Lower Kirby District an attractive choice for Lonza were the nearby life sciences community, infrastructure, and quality-of-life benefits such as top-rated schools and a reasonable cost of living.

The team at this location is currently leading efforts in four categories: research and development, process development, cell and gene therapy manufacturing, and viral vector manufacturing.

Cell and gene therapy is growing and these novel medicines are getting established as a validated treatment option — the field is transforming the way cancer or genetic diseases can be treated.

In 2019, Lonza provided manufacturing services for more than 300 commercial molecules and supported the development of more than 700 pre-clinical and clinical molecules in small and large molecules, as well as supporting the launch of pioneering autologous cell therapies.

These novel drug candidates provide drastically improved patient outcomes and, in some cases, can be curative. However, manufacturing of such medicines pose complex new challenges.

Today, the cost of production still represents a major hurdle for clinical translation and commercialization of these potentially groundbreaking therapies. New technologies are needed to enable robust and cost-efficient manufacturing of high-quality medicines.

While the therapeutic opportunities for patients are exciting, the stakes for patients and drug developers are high.

Lonza serves as a partner to its customers, keeping manufacturing costs under control and following the process through the regulatory bodies through to commercialization.

The company also helps develop and commercialize its customers' innovative new therapies. Lonza scientists and engineers bring decades-long development experience across a broad spectrum of cell types and technologies. With this background, they can tailor services in process and analytical development, manufacturing, and regulatory support.

The work done at Lonza is at the forefront of medical breakthroughs. These cell and gene therapies are shaping the way we treat modern diseases, and now it's being done right in Houston's own backyard.

Since the Pearland facility's opening in 2018, Lonza has continued to expand with the addition of laboratories, clean rooms, and additional parking.

Trending News

Building Houston

 
 

The $2.23 million deal means a growing presence Texas for Octopus Energy. Photo via octopusenergy.com

A renewable energy retailer based in the United Kingdom is once again expanding its presence in Texas with another strategic acquisition.

Octopus Energy US, which is based in Houston, announced that it has signed an agreement to acquire Houston-based energy provider Brilliant Energy LLC in a $2.23 million deal. With the acquisition, Octopus Energy will take on the 9,000 residential customers currently supplied by Brilliant Energy. These users will be transitioned onto Octopus Energy's technology platform Kraken.

"Brilliant Energy is a company that has always stood for quality and unique brand experiences. It complements our strong dedication to bringing unparalleled customer experience to our users," says Michael Lee, CEO of Octopus Energy US, in a press release. "This is a major moment for us, as we work to bring our 100% renewable energy supply and outstanding technology to more Texans and their homes."

The acquisition is the latest move from Octopus Energy's plans to invest $100 million into the U.S. energy market and target 25 million U.S. energy accounts by 2027, according to the release.

Last fall, Octopus acquired Houston-based Evolve Energy in a $5 million deal. Evolve was founded by Lee, and he transitioned into his role as Octopus CEO following the deal.

Octopus Energy, which was founded around five years ago, reached Unicorn status with a $1 billion valuation in April 2020.

Michael Lee is CEO of Octopus Energy US. Photo via LinkedIn

Trending News